Cargando…
Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial
IMPORTANCE: Many patients with focal epilepsy experience seizures despite treatment with currently available antiseizure medications (ASMs) and may benefit from novel therapeutics. OBJECTIVE: To evaluate the efficacy and safety of XEN1101, a novel small-molecule selective Kv7.2/Kv7.3 potassium chann...
Autores principales: | French, Jacqueline A., Porter, Roger J., Perucca, Emilio, Brodie, Martin J., Rogawski, Michael A., Pimstone, Simon, Aycardi, Ernesto, Harden, Cynthia, Qian, Jenny, Luzon Rosenblut, Constanza, Kenney, Christopher, Beatch, Gregory N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562989/ https://www.ncbi.nlm.nih.gov/pubmed/37812429 http://dx.doi.org/10.1001/jamaneurol.2023.3542 |
Ejemplares similares
-
TMS as a pharmacodynamic indicator of cortical activity of a novel anti‐epileptic drug, XEN1101
por: Premoli, Isabella, et al.
Publicado: (2019) -
Pharmacokinetics of XEN496, a Novel Pediatric Formulation of Ezogabine, Under Fed and Fasted Conditions: A Phase 1 Trial
por: Namdari, Rostam, et al.
Publicado: (2022) -
Capturing seizures in clinical trials of antiseizure medications for KCNQ2‐DEE
por: Millichap, John J., et al.
Publicado: (2021) -
Do neurologists agree in diagnosing drug resistance in adults with focal epilepsy?
por: Zaccara, Gaetano, et al.
Publicado: (2018) -
Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?
por: Perucca, Emilio
Publicado: (2017)